Category: Portfolio News
VUV Analytics announces $20 million financing
VUV Analytics, Inc. has announced that it has raised $20 million in equity financing—led by existing investors S3 Ventures and New Science Ventures—bringing its total funding to over $36 million. The announcement follows the recent launch of the company’s LUMA product and a record year for revenue with its unit
Read More
ProterixBio announces commercial offering of Quantitative Soluble ST2 Assay
ProterixBio, Inc. has announced the offering of the Presage® ST2 Assay as a testing service through ProterixBio’s high-complexity CLIA laboratory. This Assay has been FDA cleared for use in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Heart failure is
Read More
Picocom and Antevia Networks collaborate to provide new innovative 5G in-building solutions for enterprise private networks
Picocom, the 5G Open RAN baseband semiconductor and software specialist, has announced Antevia Networks has selected Picocom’s award-winning silicon technology to empower its new innovative 5G in-building solutions. The partnership combines Antevia Networks’ technology with Picocom’s latest generation 5G system-on-chip silicon to drive innovations to address the many challenges of
Read More
Isorg collaborates with Precise Biometrics on turnkey fingerprint sensor solution for smartphone industry
Isorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, announces further details on the company’s collaboration with Precise Biometrics, a leader in fingerprint verification software, on a new Fingerprint on Display (FoD) solution for the mobile industry. While increasing resolution unquestionably remains a major trend within the
Read MoreIsorg’s FAP30 optical fingerprint sensor obtains FBI certification
Isorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, has announced the FBI certification of Bio1Print30, a large-area optical fingerprint sensor for applications where enhanced mobile security and nomad ID authentication are key. The Bio1Print30, a FAP30 (Fingerprint Acquisition Profile) device, whose core technology is compatible with
Read More
NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes
NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has provided an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment
Read More
Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma
Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced positive data from its Phase 1/2 clinical trial evaluating the safety and clinical activity of its
Read More
Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced that the first patient has been dosed in a Phase 2 trial of its selective, allosteric TYK2 inhibitor VTX958 for
Read More
Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial
Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, has announced that its Phase II clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121). The randomized, double-blind, placebo- controlled study in patients with long covid who are suffering from debilitating fatigue has enrolled
Read MoreNovadip Biosciences raises additional EUR 40 Million bringing total company funding to EUR 88 Million
Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive
Read More
Phase Four unveils game changing engine for LEO Constellations
Leveraging its new Block 2 architecture, Phase Four announces Max-V, a revolutionary plasma propulsion system available in 2023. Phase Four, the creator of the radio-frequency thruster for satellite propulsion, has announced that it will expand its Maxwell turn-key plasma propulsion line and offer satellite manufacturers an industry-first high performance engine
Read MoreVentyx Biosciences announces positive topline Phase I data for its selective allosteric TYK2 inhibitor VTX958
Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX958, a
Read More